As the cease-fire in Gaza has ended and the fierce fighting there has resumed, the United States has issued sharper warnings to Israel’s leaders that they have a responsibility to avoid civilian casualties.Peter Baker, The Times’s chief White House correspondent, discusses the public and private ways in which President Biden is trying to influence Israel’s conduct.Guest: Peter Baker, chief White House correspondent for The New York Times.Background reading: Analysis: Biden’s strategy faces a test as Israeli forces push into southern Gaza.The U.S. is pressing Israel and Hamas to resume talks, a White House official said.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

Over the last few months, Nikki Haley has gained enough in the polls to suggest she is on the verge of surpassing Ron DeSantis as the main threat to Donald J. Trump in the race to become the Republican candidate for 2024.Jazmine Ulloa, a national politics reporter for The Times; and Nate Cohn, The Times’s chief political analyst, discuss her building momentum and examine how far she might go.Guest: Jazmine Ulloa, a national politics reporter for The New York Times.Nate Cohn, The New York Times’s chief political analyst.Background reading: Nikki Haley’s path from Trump critic to defender and back.Why is Ms. Haley’s star rising among the rivals to Mr. Trump?Here are five takeaways from the Republican debate last night.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

The opioid epidemic has been one of the biggest public health disasters in generations. The drug company at the heart of the crisis, Purdue Pharma, maker of the prescription painkiller OxyContin, agreed to a multibillion-dollar deal to settle thousands of claims against it — but that agreement would also grant the family behind the company, the Sacklers, immunity from additional civil lawsuits.Justices are now set to rule whether that settlement was legal. Abbie VanSickle, who covers the Supreme Court for The Times, explains what a decision either way could mean for the victims and for the people responsible.Guest: Abbie VanSickle, a Supreme Court correspondent for The New York Times.Background reading:What to know about the Purdue Pharma case before the Supreme Court.At the core of the matter: Who can get immunity in settlements?For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

As a racketeering trial begins in Atlanta, much of the focus is on the high-profile defendant, the best-selling rapper Young Thug.Joe Coscarelli, a culture reporter for The New York Times, explains why, in a sense, hip-hop itself is on trial.Guest: Joe Coscarelli, a culture reporter for The New York Times.Background reading: A judge ruled in November that at least 17 specific sets of lines from the Atlanta artist and his collaborators could be used by prosecutors in the racketeering trial of YSL, a chart-topping hip-hop label and collective.Here’s what to know about the trial.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

In the weeks since Hamas carried out its devastating terrorist attack in southern Israel, Times journalists have been trying to work out why the Israeli security services failed to prevent such a huge and deadly assault.Ronen Bergman, a correspondent for The New York Times, tells the story of one of the warnings that Israel ignored.Guest: Ronen Bergman, a staff writer for The New York Times Magazine.Background reading: A blueprint reviewed by The Times laid out the Oct. 7 attack in detail. Israeli officials dismissed it as aspirational.Here’s the latest on the war.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

Tech billionaire Elon Musk has come to define innovation, but he can also be a lightning rod for controversy; he recently endorsed antisemitic remarks on X, formerly known as Twitter, which prompted companies to pull their advertising. In an interview recorded live at the DealBook Summit in New York with Times business reporter and columnist Andrew Ross Sorkin, Musk discusses his emotional state and why he has “no problem being hated.”To read more news about the event, visit https://www.nytimes.com/live/2023/11/29/business/dealbook-summit-news